Caribou Biosciences to Discontinue CAR-T Programs, Opens Strategic Review
Caribou Biosciences announced on October 6, 2026 that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development of its two allogeneic CAR-T cell therapy programs, vispa-cel for relapsed or refractory B cell non-Hodgkin lymphoma and CB-011 for relapsed or refractory multiple myeloma, while implementing a substantial workforce reduction expected to be mostly complete in the fourth quarter of 2026. The Berkeley, California-based…